Department of Cardiology, Ospedali del Tigullio, Lavagna 16033, Italy.
Heart. 2012 Dec;98(23):1738-42. doi: 10.1136/heartjnl-2012-302536. Epub 2012 Sep 28.
To evaluate the consequence of treatment delay of primary percutaneous coronary intervention (PPCI) on long-term survival.
Network organisation based on early recognition, shortening prehospital time delays and procedural delays is the cornerstone of optimal clinical results in the acute phase of ST-segment elevation myocardial infarction (STEMI). Nevertheless, the evidence of a relationship between symptom onset-to-balloon time and mortality is weak, and few long-term data are available. SETTING AND MEASURES: In this single-centre observational follow-up study, we evaluated the long-term survival of 790 consecutive STEMI patients (mean age 68 ± 13 years; 73% males) undergoing PPCI ≤ 12 h from symptom onset, or 12-36 h in the case of persistence of symptoms or hemodynamic instability.
The median (IQR) treatment delay, defined as the time from symptom onset to reperfusion, was 180 min (120;310), fairly balanced between patient delay (80 min (40;140)) and system delay (80 min (60-114)). Patients with a treatment delay <180 min displayed lower mortality at 1, 3, 5 and 7 years (12%, 17%, 22% and 26%, respectively) than those with a treatment delay >180 min (15%, 24%, 28% and 37%, respectively). The HR was 0.7 (95% CI 0.5 to 0.9). On univariate and stepwise multiple regression analysis, field triage and transportation (p=0.0001), shorter distance from hospital (p=0.02) and male gender (p=0.02), but not clinical variables, were independent predictors of shorter treatment delay.
Shorter symptom onset-to-balloon time predicts long-term lower mortality in STEMI patients treated with PPCI. Our findings emphasise the need to minimise any component of treatment delay.
评估直接经皮冠状动脉介入治疗(PPCI)治疗延迟对长期生存的影响。
基于早期识别、缩短院前时间延迟和操作延迟的网络组织是 ST 段抬高型心肌梗死(STEMI)急性期获得最佳临床效果的基石。然而,症状发作至球囊时间与死亡率之间的关系证据不足,且可用的长期数据有限。
在这项单中心观察性随访研究中,我们评估了 790 例连续 STEMI 患者(平均年龄 68 ± 13 岁;73%为男性)的长期生存情况,这些患者在症状发作后 12 小时内或在症状持续或血流动力学不稳定的情况下 12-36 小时内行 PPCI。
中位(IQR)治疗延迟(定义为从症状发作到再灌注的时间)为 180 分钟(120;310),在患者延迟(80 分钟(40;140))和系统延迟(80 分钟(60-114))之间基本平衡。治疗延迟<180 分钟的患者在 1、3、5 和 7 年时的死亡率较低(分别为 12%、17%、22%和 26%),而治疗延迟>180 分钟的患者的死亡率较高(分别为 15%、24%、28%和 37%)。风险比为 0.7(95%置信区间 0.5 至 0.9)。在单变量和逐步多变量回归分析中,现场分诊和转运(p=0.0001)、与医院的距离较短(p=0.02)和男性(p=0.02),而不是临床变量,是治疗延迟更短的独立预测因素。
STEMI 患者接受 PPCI 治疗时,症状发作至球囊时间越短,长期死亡率越低。我们的研究结果强调了需要尽量减少治疗延迟的任何组成部分。